-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9

Benzinga·08/20/2026 13:12:16
Listen to the news
Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.